- Home
- ICCM vs NSPR Comparison
ICCM vs NSPR Comparison
Compare ICCM & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- NSPR
- Stock Information
- Founded
- ICCM 2006
- NSPR 2005
- Country
- ICCM Israel
- NSPR United States
- Employees
- ICCM N/A
- NSPR N/A
- Industry
- ICCM
- NSPR Medical/Dental Instruments
- Sector
- ICCM
- NSPR Health Care
- Exchange
- ICCM Nasdaq
- NSPR Nasdaq
- Market Cap
- ICCM 70.1M
- NSPR 75.6M
- IPO Year
- ICCM N/A
- NSPR N/A
- Fundamental
- Price
- ICCM $1.24
- NSPR $2.61
- Analyst Decision
- ICCM Strong Buy
- NSPR Strong Buy
- Analyst Count
- ICCM 1
- NSPR 2
- Target Price
- ICCM $2.50
- NSPR $4.75
- AVG Volume (30 Days)
- ICCM 340.9K
- NSPR 64.7K
- Earning Date
- ICCM 03-27-2025
- NSPR 05-13-2025
- Dividend Yield
- ICCM N/A
- NSPR N/A
- EPS Growth
- ICCM N/A
- NSPR N/A
- EPS
- ICCM N/A
- NSPR N/A
- Revenue
- ICCM $3,291,000.00
- NSPR $7,009,000.00
- Revenue This Year
- ICCM $75.63
- NSPR $28.93
- Revenue Next Year
- ICCM $69.36
- NSPR $172.18
- P/E Ratio
- ICCM N/A
- NSPR N/A
- Revenue Growth
- ICCM 1.92
- NSPR 12.96
- 52 Week Low
- ICCM $0.48
- NSPR $1.81
- 52 Week High
- ICCM $1.66
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- ICCM 46.87
- NSPR 38.11
- Support Level
- ICCM $1.04
- NSPR $2.57
- Resistance Level
- ICCM $1.25
- NSPR $2.71
- Average True Range (ATR)
- ICCM 0.10
- NSPR 0.17
- MACD
- ICCM -0.01
- NSPR -0.02
- Stochastic Oscillator
- ICCM 40.82
- NSPR 24.00
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.